[ad_1]
Pdl Biopharma Inc. (NASDAQ: PDLI) up 1.23% to close at $ 2.47. The stock has a market capitalization of $ 368.92 million, but its outstanding shares are 149.36 million. The beta value of the company was established at 0.38
Pdl Biopharma Inc. (NASDAQ: PDLI) has a solvency ratio of 3, which corresponds to the overall results of # 39, a survey of badysts. According to the Zacks simplified downgrade scale, the ABR rank is displayed in the range of 1 to 5, where 1 represents Strong Buy and 5 Strong Sell. As its name indicates, ABR will show you the average brokerage recommendations on a given stock. It helps you quickly get an image of where Wall Street lies on a stock without reading huge research reports. The smallest number of ABR is the most favorable. The modest value of the stock is known as the current ABR of the stock.
However about 1 badysts 0 suggest Pdl Biopharma Inc. (NASDAQ: PDLI) a strong buy, 0 suggested buying, 1 hold and 0 sell, while 0 badysts expect an estimate of average profits of 0, $ 06 for the current quarter, according to the opinion of 1 badysts, with respect to estimates of $ 0.06 for high earnings per share and $ 0.06 for low estimates, however Pdl Biopharma Inc (NASDAQ: PDLI) reported $ 0.39 earnings per share for the same quarter last year.
For the current quarter Pdl Biopharma Inc. (NASDAQ: PDLI) has average revenue estimates of $ 44.66 million, a total number of 1 badysts provided revenue estimates. However, low revenue estimates for the company are $ 44.66 million against high revenue estimates of $ 44.66 million. A year ago, the company's sales were $ 14,340 while its annual sales growth estimates for the current quarter are -69%.
Brokerage firms have a target of $ 2.5 on Pdl Biopharma Inc. (NASDAQ: PDLI). Brokerage companies on the street have price targets on the name ranging from $ 2.5 to $ 2.5 based on 1 opinions.
Pdl Biopharma Inc. (NASDAQ: PDLI) in the current trade, showed a weekly performance of 6.47% which was maintained at -6.08% over a period of one month. Performance since the beginning of the year remained at -9.85%. In the past three months, the stock has gained -18.75%, but the performance of the six-month stock has remained at -14.24%. The price of Pdl Biopharma Inc. (NASDAQ: PDLI) is down -9.04% from its SMA 50 of $ 2.63 and -14.36% over the SMA 200 of 2.77%. $
Currently Pdl Biopharma Inc. (NASDAQ: PDLI)'s shares held by insiders are 1%, while shares held by institutional owners are 90.8%. However, the six-month change in insider property was recorded at 0%, as was the three-month change in institutional ownership of -4.14%.
The stock traded at -30.4% and 14.88% far from the low point of the stock over the past 52 weeks, or $ 2.15
The stock / price ratio earnings (P / E ratio) is the valuation ratio of a company that measures its current price relative to its price. -Share gains. The price / earnings ratio of Pdl Biopharma Inc (NASDAQ: PDLI) is 3.61. A high P / E suggests that investors expect higher earnings growth in the future compared to companies with lower P / E. A low P / E may indicate that a company may currently be undervalued or that the company is doing exceptionally well in relation to its past trends.
The PEG ratio is used to determine the value of an equity while taking into account earnings growth. , and is considered to provide a more complete picture than the P / E. Pdl Biopharma Inc. (NASDAQ: PDLI) has a current PEG of 0.26. The price / sales ratio of Pdl Biopharma Inc. (NASDAQ: PDLI) for the last twelve months is 1.18, while its price-to-book ratio for the most recent quarters is 0.44. However, the price of the company compared to the last quarter set at 2.71. Its free cash flow price for the last twelve months is 0.91
.
[ad_2]
Source link
